Rune Kjeken is Scientific Director for Advanced Therapies at the Norwegian Medicine Agency, and a member of the European Medicines Agency’s Committee for Advanced Therapy (CAT) and the Scientific Advice Working Party (SAWP). He was previously a member of EMA’s Gene Therapy Working Party (GTWP). His work is primarily focused on preclinical and clinical regulatory issues regarding the development of cell and gene therapies for rare diseases and cancer.
Prior to joining the Norwegian Medicines Agency in 2009, he served as Executive Director for Research & Development at Inovio Biomedical Company, San Diego, developing methods for non-viral gene delivery and the development of therapeutic DNA vaccines for cancer and infectious diseases.
Rune Kjeken holds a PhD in molecular biology from the University of Oslo and received his Post-doctoral training at the European Molecular Biology Laboratory (EMBL) in Heidelberg.